HLN vs. CNC, ALC, IDXX, TAK, HUM, IQV, MRNA, GEHC, RMD, and BIIB
Should you be buying Haleon stock or one of its competitors? The main competitors of Haleon include Centene (CNC), Alcon (ALC), IDEXX Laboratories (IDXX), Takeda Pharmaceutical (TAK), Humana (HUM), IQVIA (IQV), Moderna (MRNA), GE HealthCare Technologies (GEHC), ResMed (RMD), and Biogen (BIIB). These companies are all part of the "medical" sector.
Haleon (NYSE:HLN) and Centene (NYSE:CNC) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.
Centene has a consensus price target of $85.23, indicating a potential upside of 12.29%. Given Centene's higher probable upside, analysts plainly believe Centene is more favorable than Haleon.
Centene received 1002 more outperform votes than Haleon when rated by MarketBeat users. Likewise, 73.25% of users gave Centene an outperform vote while only 39.29% of users gave Haleon an outperform vote.
Haleon has a net margin of 9.68% compared to Centene's net margin of 1.76%. Centene's return on equity of 14.19% beat Haleon's return on equity.
In the previous week, Centene had 12 more articles in the media than Haleon. MarketBeat recorded 19 mentions for Centene and 7 mentions for Haleon. Centene's average media sentiment score of 0.73 beat Haleon's score of 0.30 indicating that Centene is being referred to more favorably in the news media.
Haleon has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500. Comparatively, Centene has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500.
Centene has higher revenue and earnings than Haleon. Centene is trading at a lower price-to-earnings ratio than Haleon, indicating that it is currently the more affordable of the two stocks.
6.7% of Haleon shares are owned by institutional investors. Comparatively, 93.6% of Centene shares are owned by institutional investors. 0.3% of Centene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Centene beats Haleon on 13 of the 18 factors compared between the two stocks.
Get Haleon News Delivered to You Automatically
Sign up to receive the latest news and ratings for HLN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
